Profile data is unavailable for this security.
About the company
TMS Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and marketing of pharmaceuticals. The Company conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.
- Revenue in JPY (TTM)0.00
- Net income in JPY-1.06bn
- Incorporated2005
- Employees14.00
- LocationTMS Co Ltd5F, Sekiguchi Bldg., 1-23-3, Miya-machiFUCHU-SHI 183-0055JapanJPN
- Phone+81 423077480
- Fax+81 423065078
- Websitehttps://www.tms-japan.co.jp/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BrightPath Biotherapeutics Co Ltd | 84.00k | -1.20bn | 4.11bn | 24.00 | -- | 5.19 | -- | 48,878.26 | -18.25 | -18.25 | 0.0013 | 9.44 | 0.00008 | -- | 3.50 | 3,500.00 | -108.84 | -51.56 | -116.51 | -54.32 | 75.00 | 68.63 | -1,431,842.00 | -22,321.82 | -- | -274.19 | 0.00 | -- | -98.64 | -78.47 | 21.37 | -- | -46.55 | -- |
FunPep Co Ltd | 530.00k | -727.29m | 4.41bn | 15.00 | -- | 1.65 | -- | 8,316.22 | -29.40 | -29.40 | 0.0215 | 82.55 | 0.0002 | -- | -- | 35,333.33 | -26.27 | -27.10 | -29.12 | -28.75 | -- | -- | -137,223.40 | -815.82 | 5.06 | -1,004.01 | 0.00 | -- | -50.33 | -72.80 | 20.39 | -- | -13.14 | -- |
Cyfuse Biomedical KK | 60.88m | -671.82m | 4.71bn | 21.00 | -- | 1.61 | -- | 77.34 | -84.88 | -84.88 | 7.71 | 360.49 | 0.0148 | 0.5613 | 24.17 | 2,899,143.00 | -16.32 | -- | -19.11 | -- | 58.30 | -- | -1,103.48 | -- | 6.02 | -84.25 | 0.2153 | -- | -83.68 | -- | -24.32 | -- | -- | -- |
Kidswell Bio Corp | 2.87bn | -1.13bn | 4.80bn | 42.00 | -- | 6.51 | -- | 1.67 | -30.62 | -30.62 | 77.19 | 18.12 | 0.7495 | 1.37 | 7.46 | 68,290,810.00 | -29.48 | -57.41 | -47.94 | -81.13 | 42.46 | 55.20 | -39.33 | -123.52 | 1.45 | -22.17 | 0.7709 | -- | -12.43 | 18.93 | -116.31 | -- | -- | -- |
DNA Chip Research Inc | 629.13m | -172.44m | 4.97bn | 37.00 | -- | 6.98 | -- | 7.91 | -26.95 | -26.95 | 97.41 | 105.25 | 0.739 | 9.29 | 5.94 | 17,003,490.00 | -20.25 | -23.49 | -24.51 | -26.70 | 28.19 | 14.28 | -27.41 | -54.10 | 2.98 | -926.97 | 0.00 | -- | 49.74 | 6.33 | 31.48 | -- | -15.75 | -- |
Kringle Pharma Inc | 79.22m | -793.94m | 5.97bn | 13.00 | -- | 2.55 | -- | 75.38 | -134.08 | -134.08 | 13.09 | 344.17 | 0.0274 | -- | 1.66 | 6,093,462.00 | -27.49 | -19.00 | -29.10 | -20.23 | -- | -- | -1,002.26 | -156.51 | 30.96 | -- | 0.00 | -- | -82.33 | -- | -157.41 | -- | -- | -- |
Carna Biosciences, Inc. | 1.44bn | -1.36bn | 6.27bn | 67.00 | -- | 1.95 | -- | 4.35 | -78.70 | -78.70 | 83.68 | 178.16 | 0.3493 | 1.22 | 9.81 | 21,506,880.00 | -33.00 | -14.45 | -36.04 | -16.95 | 87.84 | 90.59 | -94.48 | -35.42 | 9.17 | -- | 0.0268 | -- | 17.24 | 16.59 | 14.57 | -- | -27.69 | -- |
Chiome Bioscience Inc | 587.30m | -1.12bn | 6.37bn | 51.00 | -- | 5.48 | -- | 10.85 | -21.19 | -21.19 | 11.09 | 18.99 | 0.3622 | 4.68 | 7.96 | 11,515,750.00 | -69.09 | -50.50 | -96.39 | -57.38 | 55.28 | 57.53 | -190.76 | -224.74 | 3.17 | -816.71 | 0.2144 | -- | 8.19 | 26.24 | 1.84 | -- | -- | -- |
Modalis Therapeutics Corp | 0.00 | -2.14bn | 6.98bn | 37.00 | -- | 3.97 | -- | -- | -64.28 | -64.28 | 0.00 | 28.21 | 0.00 | -- | -- | 0.00 | -100.32 | -29.19 | -110.17 | -30.02 | -- | -- | -- | -597.35 | 12.87 | -- | 0.1274 | -- | -100.00 | -- | 11.50 | -- | 135.50 | -- |
Veritas In Silico Inc | -100.00bn | -100.00bn | 7.38bn | 15.00 | -- | 3.13 | -- | -- | -- | -- | -- | 363.16 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 63.22 | -- | 0.00 | -- | 101.54 | -- | 123.38 | -- | -- | -- |
TMS Co Ltd | 0.00 | -1.06bn | 7.58bn | 14.00 | -- | 2.36 | -- | -- | -27.96 | -27.96 | 0.00 | 79.72 | 0.00 | -- | -- | 0.00 | -30.42 | -- | -31.24 | -- | -- | -- | -- | -- | 29.35 | -1,052.64 | 0.00 | -- | -- | -- | -11.51 | -- | -- | -- |
Noile-Immune Biotech Inc | 308.06m | -979.88m | 7.92bn | 28.00 | -- | 1.58 | -- | 25.72 | -22.63 | -22.63 | 7.11 | 115.62 | 0.0549 | 0.0625 | 6.35 | 11,002,180.00 | -17.47 | -- | -17.90 | -- | 99.80 | -- | -318.08 | -- | 66.40 | -- | 0.00 | -- | -49.37 | -- | -192.28 | -- | -- | -- |
Linical Co Ltd | 12.15bn | 252.44m | 9.65bn | 662.00 | 34.89 | 1.08 | 12.25 | 0.794 | 11.18 | 11.18 | 538.03 | 362.32 | 0.6633 | -- | 3.45 | 18,356,870.00 | 1.38 | 4.01 | 2.37 | 6.33 | 29.26 | 30.99 | 2.08 | 5.48 | -- | -- | 0.2518 | 50.81 | -1.67 | 1.70 | -66.32 | -9.86 | -10.18 | 4.56 |
OncoTherapy Science, Inc. | 562.70m | -1.19bn | 10.05bn | 54.00 | -- | 13.24 | -- | 17.86 | -5.39 | -5.39 | 2.55 | 2.80 | 0.4431 | 5.18 | 15.94 | 10,420,280.00 | -93.70 | -55.67 | -129.70 | -63.82 | -30.63 | -1.49 | -211.47 | -247.47 | 2.67 | -255.18 | 0.1146 | -- | -46.24 | 16.81 | -15.15 | -- | -48.33 | -- |
3-D Matrix Ltd | 5.25bn | -1.05bn | 10.55bn | 106.00 | -- | 9.18 | -- | 2.01 | -12.89 | -12.89 | 66.88 | 11.66 | 0.8559 | 0.551 | 5.40 | 49,502,420.00 | -17.15 | -42.10 | -21.31 | -55.60 | 68.38 | 53.95 | -20.04 | -96.03 | 2.51 | -- | 0.7979 | -- | 98.30 | 69.41 | 89.55 | -- | -30.34 | -- |
Medinet Co Ltd | 759.11m | -1.34bn | 11.11bn | 98.00 | -- | 2.07 | -- | 14.64 | -5.53 | -5.53 | 3.10 | 20.31 | 0.1347 | 11.64 | 3.73 | 7,745,980.00 | -23.85 | -21.05 | -24.99 | -22.47 | 17.78 | 28.75 | -177.09 | -135.40 | 18.90 | -- | 0.00 | -- | 4.40 | -7.90 | -14.66 | -- | -17.67 | -- |
Holder | Shares | % Held |
---|---|---|
RTW Investments LPas of 31 Jan 2024 | 3.61m | 8.95% |
Simplex Asset Management Co., Ltd.as of 04 Jul 2024 | 77.50k | 0.19% |